Author:
Zampieri Fernando G.,Westphal Glauco Adrieno,Santos Maria Adelaide Dos,Gomes Samara P.C.,Gomes Jackeline O.,Negrelli Karina L.,Santos Renato H.N.,Ishihara Luciana M.,Miranda Tamiris A.,Laranjeira Ligia N.,Valeis Nanci,Santucci Eliana Vieira,de Souza Dantas Vicente Cés,Gebara Otávio,Cohn Danny M.,Buchele Gustavo,Janiszewski Mariano,de Freitas Flávio Geraldo,Dal-Pizzol Felipe,de Matos Soeiro Alexandre,Berti Isabele Ribeiro,Germano Almir,Schettini Daniel Almeida,Rosa Regis G.,Falavigna Maicon,Veiga Viviane C.,Azevedo Luciano C.P.,Damiani Lucas P.,Machado Flávia R.,Cavalcanti Alexandre B.
Funder
Ionis Pharmaceuticals Inc
Reference17 articles.
1. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area;Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium; Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP;JAMA,2020
2. Future scenarios for the COVID-19 pandemic;Skegg;Lancet,2021
3. Dexamethasone in Hospitalized Patients with Covid-19;Horby;N Engl J Med,2021
4. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19;Kalil;N Engl J Med,2021
5. STOP-COVID trial investigators. Tofacitinib in patients hospitalized with Covid-19 pneumonia;Guimarães;N Engl J Med,2021